Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRTC Stock Forecast 2025-2026
$16.78
Current Price
$403.06M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PRTC Price Targets
+260.5%
To High Target of $60.50
+217.3%
To Median Target of $53.25
+174.1%
To Low Target of $46.00
PRTC Price Momentum
-5.9%
1 Week Change
+3.8%
1 Month Change
-38.9%
1 Year Change
-9.1%
Year-to-Date Change
-49.1%
From 52W High of $32.98
+26.2%
From 52W Low of $13.30
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching PureTech (PRTC) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PRTC and similar high-potential opportunities.
Latest PRTC Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PRTC has a bullish consensus with a median price target of $53.25 (ranging from $46.00 to $60.50). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $16.78, the median forecast implies a 217.3% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRTC Analyst Ratings
2
Buy
0
Hold
0
Sell
PRTC Price Target Range
Low
$46.00
Average
$53.25
High
$60.50
Current: $16.78
Latest PRTC Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRTC.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 9, 2024 | Leerink Partners | Faisal Khurshid | Outperform | Assumes | $45.00 |
| Aug 26, 2022 | Piper Sandler | Overweight | Maintains | $0.00 | |
| Aug 25, 2022 | Piper Sandler | Edward Tenthoff | Overweight | Maintains | $44.00 |
| Aug 9, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $70.00 |
| Jun 15, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $66.00 |
| Jan 7, 2022 | SVB Leerink | Thomas Smith | Outperform | Maintains | $70.00 |
| Aug 25, 2021 | SVB Leerink | Thomas Smith | Outperform | Maintains | $76.00 |
| Jan 15, 2021 | SVB Leerink | Outperform | Initiates | $0.00 |
PureTech Health plc - ADR (PRTC) Competitors
The following stocks are similar to PureTech based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PRTC
PureTech Health
mkt cap
403.06M
PureTech Health plc - ADR (PRTC) Financial Data
PureTech Health plc - ADR has a market capitalization of $403.06M with a P/E ratio of 8.0x. The company generates $4.83M in trailing twelve-month revenue with a 1,108.3% profit margin.
Revenue growth is +2,422.2% quarter-over-quarter, while maintaining an operating margin of -1,530.2% and return on equity of +6.4%.
Valuation Metrics
Market Cap
$403.06M
Enterprise Value
$3.91B
P/E Ratio
8.0x
PEG Ratio
-33.6x
Price/Sales
83.5x
Growth & Margins
Revenue Growth (YoY)
+2,422.2%
Gross Margin
N/A
Operating Margin
-1,530.2%
Net Margin
+1,108.3%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+9.4%
Current Ratio
9.3x
Debt/Equity
40.6x
ROE
+6.4%
ROA
-13.1%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
PureTech Health plc - ADR (PRTC) Business Model
About PureTech Health plc - ADR
What They Do
Biotechnology company developing innovative therapies.
Business Model
The company discovers and develops new therapies targeting significant medical challenges in immunology, oncology, and neuroscience. It generates revenue through the commercialization of these advanced medicines, leveraging its unique scientific approaches and expertise.
Additional Information
As an American Depositary Receipt (ADR), PureTech Health plc provides US investors access to its shares traded on the London Stock Exchange, enhancing its market reach. The company's commitment to addressing previously untapped biological and clinical pathways positions it as a notable player in the healthcare sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
80
CEO
Dr. Bharatt M. Chowrira J.D., Ph.D.
Country
United States
IPO Year
2020
Website
www.puretechhealth.comPureTech Health plc - ADR (PRTC) Latest News & Analysis
Latest News
Quick Summary
PureTech announced the publication of new research focusing on the experiences of individuals living with Idiopathic Pulmonary Fibrosis (IPF).
Why It Matters
New research on IPF could impact PureTech's stock by influencing investor perception of its therapeutic potential and market opportunities in a growing healthcare sector.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech Health plc will hold its Q4 2024 earnings call on April 30, 2025, at 9:00 AM ET, featuring executives including CEO Bharatt Chowrira and Senior VP Allison Mead Talbot.
Why It Matters
PureTech Health's Q4 earnings call indicates upcoming financial performance insights, which could influence stock valuation and investor sentiment. Key participants suggest strategic discussions ahead.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
PureTech announced its annual results for the year ended December 31, 2024. Further details on financial performance and outlook may be available in the full report.
Why It Matters
PureTech's annual results can signal financial health and growth prospects, impacting stock valuation and investor sentiment. Strong performance may attract investment, while weak results could lead to sell-offs.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech will present Phase 2b trial results for Deupirfenidone (LYT-100) in treating idiopathic pulmonary fibrosis at the American Thoracic Society International Conference.
Why It Matters
The presentation of Phase 2b trial results for LYT-100 could influence PureTech's stock price, signaling potential advancements in treatment for IPF and impacting market perceptions.
Source: Business Wire
Market Sentiment:
Neutral
PureTech Health: Notice of Results
19 days ago
Quick Summary
PureTech Health has announced a notice of results, indicating upcoming financial disclosures that may impact investor decisions.
Why It Matters
PureTech Health's notice of results signals upcoming financial disclosures, which can impact stock performance and investor confidence based on earnings and growth forecasts.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
PureTech has appointed Peel Hunt as its joint corporate broker in the UK, indicating a strategic move to enhance its corporate finance capabilities.
Why It Matters
PureTech's appointment of Peel Hunt as a corporate broker signals strategic moves in the UK market, potentially enhancing investor confidence and facilitating capital raising opportunities.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About PRTC Stock
What is PureTech Health plc - ADR's (PRTC) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, PureTech Health plc - ADR (PRTC) has a median price target of $53.25. The highest price target is $60.50 and the lowest is $46.00.
Is PRTC stock a good investment in 2025?
According to current analyst ratings, PRTC has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $16.78. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRTC stock?
Wall Street analysts predict PRTC stock could reach $53.25 in the next 12 months. This represents a 217.3% increase from the current price of $16.78. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is PureTech Health plc - ADR's business model?
The company discovers and develops new therapies targeting significant medical challenges in immunology, oncology, and neuroscience. It generates revenue through the commercialization of these advanced medicines, leveraging its unique scientific approaches and expertise.
What is the highest forecasted price for PRTC PureTech Health plc - ADR?
The highest price target for PRTC is $60.50 from at , which represents a 260.5% increase from the current price of $16.78.
What is the lowest forecasted price for PRTC PureTech Health plc - ADR?
The lowest price target for PRTC is $46.00 from at , which represents a 174.1% increase from the current price of $16.78.
What is the overall PRTC consensus from analysts for PureTech Health plc - ADR?
The overall analyst consensus for PRTC is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $53.25.
How accurate are PRTC stock price projections?
Stock price projections, including those for PureTech Health plc - ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 12, 2025 11:40 AM UTC